Changing Perspective for Treatment of Chronic Kidney Disease / / Giacomo Garibotto.
Chronic kidney disease (CKD) has become an enormous worldwide health problem, both in developed and less developed countries. The incidence and prevalence of CKD is high, and is associated with increased mortality and morbidity. Of note, CKD is the 12th most common primary cause of death, accounting...
Saved in:
VerfasserIn: | |
---|---|
Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (158 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562105004498 |
---|---|
ctrlnum |
(CKB)4920000001372690 (NjHacI)994920000001372690 (EXLCZ)994920000001372690 |
collection |
bib_alma |
record_format |
marc |
spelling |
Garibotto, Giacomo, author. Changing Perspective for Treatment of Chronic Kidney Disease / Giacomo Garibotto. Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2022. 1 online resource (158 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (MDPI, viewed February 19, 2023). Chronic kidney disease (CKD) has become an enormous worldwide health problem, both in developed and less developed countries. The incidence and prevalence of CKD is high, and is associated with increased mortality and morbidity. Of note, CKD is the 12th most common primary cause of death, accounting for about 1 million deaths per year worldwide. CKD and end-stage renal disease are characterized by the progressive development of a series of complications, such as anemia, hyperkalemia, hypervolemia, mineral and bone disorders (CKD-MBD), metabolic acidosis, hyperuricemia and wasting; all of these complications have been shown to be associated with adverse outcomes, and can contribute either individually or in association to the cardiovascular morbidity and mortality observed in CKD. While at this time CKD progression is not treated with high efficacy, new biomarkers of kidney fibrosis have become available in recent years and new treatments for kidney fibrosis and cell loss could become soon available. In addition recent progress in our understanding of CKD pathophysiology together with the development of novel therapeutic agents has led to a renewed attention on the treatment of CKD-associated metabolic complications which are now are amenable to therapeutic interventions. All these important issues are addressed in this volume. Kidneys Diseases. 3-0365-2795-8 |
language |
English |
format |
eBook |
author |
Garibotto, Giacomo, |
spellingShingle |
Garibotto, Giacomo, Changing Perspective for Treatment of Chronic Kidney Disease / |
author_facet |
Garibotto, Giacomo, |
author_variant |
g g gg |
author_role |
VerfasserIn |
author_sort |
Garibotto, Giacomo, |
title |
Changing Perspective for Treatment of Chronic Kidney Disease / |
title_full |
Changing Perspective for Treatment of Chronic Kidney Disease / Giacomo Garibotto. |
title_fullStr |
Changing Perspective for Treatment of Chronic Kidney Disease / Giacomo Garibotto. |
title_full_unstemmed |
Changing Perspective for Treatment of Chronic Kidney Disease / Giacomo Garibotto. |
title_auth |
Changing Perspective for Treatment of Chronic Kidney Disease / |
title_new |
Changing Perspective for Treatment of Chronic Kidney Disease / |
title_sort |
changing perspective for treatment of chronic kidney disease / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2022 |
physical |
1 online resource (158 pages) |
isbn |
3-0365-2795-8 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC902 |
callnumber-sort |
RC 3902 G375 42022 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.61 |
dewey-sort |
3616.61 |
dewey-raw |
616.61 |
dewey-search |
616.61 |
work_keys_str_mv |
AT garibottogiacomo changingperspectivefortreatmentofchronickidneydisease |
status_str |
n |
ids_txt_mv |
(CKB)4920000001372690 (NjHacI)994920000001372690 (EXLCZ)994920000001372690 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Changing Perspective for Treatment of Chronic Kidney Disease / |
_version_ |
1764993821513351168 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02310nam a2200277 i 4500</leader><controlfield tag="001">993562105004498</controlfield><controlfield tag="005">20230219185946.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230219s2022 sz o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000001372690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000001372690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000001372690</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC902</subfield><subfield code="b">.G375 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.61</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garibotto, Giacomo,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Changing Perspective for Treatment of Chronic Kidney Disease /</subfield><subfield code="c">Giacomo Garibotto.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (158 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (MDPI, viewed February 19, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic kidney disease (CKD) has become an enormous worldwide health problem, both in developed and less developed countries. The incidence and prevalence of CKD is high, and is associated with increased mortality and morbidity. Of note, CKD is the 12th most common primary cause of death, accounting for about 1 million deaths per year worldwide. CKD and end-stage renal disease are characterized by the progressive development of a series of complications, such as anemia, hyperkalemia, hypervolemia, mineral and bone disorders (CKD-MBD), metabolic acidosis, hyperuricemia and wasting; all of these complications have been shown to be associated with adverse outcomes, and can contribute either individually or in association to the cardiovascular morbidity and mortality observed in CKD. While at this time CKD progression is not treated with high efficacy, new biomarkers of kidney fibrosis have become available in recent years and new treatments for kidney fibrosis and cell loss could become soon available. In addition recent progress in our understanding of CKD pathophysiology together with the development of novel therapeutic agents has led to a renewed attention on the treatment of CKD-associated metabolic complications which are now are amenable to therapeutic interventions. All these important issues are addressed in this volume.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Kidneys</subfield><subfield code="x">Diseases.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2795-8</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 01:57:16 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337957780004498&Force_direct=true</subfield><subfield code="Z">5337957780004498</subfield><subfield code="8">5337957780004498</subfield></datafield></record></collection> |